Others also reported high rates of homologous recombination-related gene mutations in ACC cases compared to pancreatic ductal adenocarcinoma (PDAC), including mutations of BRCA2 (13.6%), BRCA1 (2.3%), and ATM (11.4%); they also reported that 25% had mutations of at least one of five genes (ATM, ATR, BRCA1, BRCA2, and PALB2) [4]. This evidence concerns the gene BRCA1 and pancreatic ductal adenocarcinoma.